Moleculin Biotech Inc

NASDAQ:MBRX   3:59:41 PM EDT
3.42
-0.01 (-0.29%)
Products

Moleculin Receives FDA Approval Of Fast Track Designation For Annamycin In The Treatment Of Sarcoma Lung Metastases

Published: 03/30/2021 12:18 GMT
Moleculin Biotech Inc (MBRX) - Moleculin Receives FDA Approval of Fast Track Designation for Annamycin in the Treatment of Sarcoma Lung Metastases.